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ABSTRACT: In this paper, we describe the latest results involving molecular modeling and pharmacodynamic studies of the
selected highly lipophilic compounds acting by human GABA transporter 1 (hGAT1) inhibition. The chemical interaction of 17
GABA analogues with a model of hGAT1 is described using the molecular docking method. The biological role of GAT1 is
related to the regulation of GABA level in the central nervous system and GAT1 inhibition plays an important role in the
control of seizure threshold. To confirm that GAT1 can be also a molecular target for drugs used to treat other neurological and
psychiatric diseases (e.g., pain and anxiety), in the in vivo part of this study, potential antinociceptive and anxiolytic-like
properties of tiagabine, a selective GAT1 inhibitor, are described.
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■ INTRODUCTION
4-Aminobutanoic acid (GABA) is the main inhibitory neuro-
transmitter in the mammalian brain and spinal cord.1−5 The
GABAergic signal termination depends on its clearance by
GABA transporters (GATs) which quickly remove this main
inhibitory neurotransmitter from the synaptic cleft. This modu-
lation of GABA levels highlights the importance of GATs as
potential targets to regulate many physiological processes in
which GABAergic transmission is involved, including seizure
threshold, pain, and mood control.6−9
There is a large volume of published studies describing the
GAT location in different cell types, including neurons and
astrocytes, with variable expression levels across different brain
regions.10 Likewise, other evidence suggests that GABA could
be taken up into neurons but was also actively accumulated
into glial cells.11 From many neuronal cell and astrocyte
culture studies, it is clear that these cells could play a significant
role in the removal of GABA from the synaptic cleft. There is,
however, evidence that the transport capacity for GABA
cannot be characterized strictly as neuronal or glial transport
GABA.11,12 There is a consensus among pharmacologists for
the existence of five subtypes of high-affinity GATs located on
neurons and astrocytes in different species. At present, four
subtypes of plasma membrane human transporters for GABA
have been identified, namely: GAT1, BGT1, GAT2, and
GAT3.13,14 GAT1 and GAT3 have the highest expressions,
being predominantly located on GABAergic nerve terminals
and abundantly expressed in the mammalian central nervous
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system (CNS).1,2 GAT1 is a primary neuronal and some
astrocyte cells GAT, while GAT3 is commonly associated with
distal astrocytic site.13,15,16 More recent studies have confirmed
that GAT1 expression highly resembles GABAergic pathways.5,17
It is noteworthy that widespread distribution of GABAergic
neurons and the inhibition of GAT systems may modify seizure
threshold and control the propagation of pain signals.18−20
Considering the aforementioned facts, the aim of this study
is a detailed analysis of the interactions between the human
GAT1 (hGAT1) and antiepileptic drugs, and active com-
pounds and their structures. The objective of this paper is to
perform the in silico study on the series of 17 highly lipophilic
GABA uptake inhibitors. The in silico part describes a detailed
analysis of the hydrogen bonds found in the complexes. In
order to better understand the mechanism of action displayed
by the tested compounds, we focused on their influence on the
neurons and astrocytes cells at the molecular level. GABAergic
drugs acting at various targets within the GABAergic synapses
(i.e., GABAergic receptors, GAT, GABA transaminase) are
widely used in medicine for the treatment of several patholo-
gies of the central and peripheral nervous system. Apart from
their wide application in epilepsy, they have been found very
useful in the therapy of some nonepileptic conditions.21,22 It is
noteworthy that recently, a physiological level of GABA in the
brain has been also found to play an important protective role
in obsessive-compulsive disorder (OCD).23 Although OCD is
strongly related to the deficits in serotonergic neurotrans-
mission and drugs that inhibit serotonin reuptake are con-
sidered drug treatments of choice for this disorder,24 it has
been also shown that reduced GABAergic activity with a con-
comitant excessive glutamatergic neurotransmission are pre-
sent in patients suffering from OCD.23
Due to the role of GABA as the main functional component
of the “pain gate” in the CNS,25,26 GABAergic drugs proved their
significant analgesic efficacy in many chronic pain syndromes.
Newer studies clearly indicate that GABA might be also involved
in pain transduction and signal transmission in the periphery.27
There is also evidence for a role of GABAergic mechanisms in
the attenuation of neurogenic inflammation.28−30
In view of the above-mentioned findings, in the in vivo part
of the present study, we aimed to assess if the inhibition of
GAT1 might (1) attenuate behavioral symptoms of OCD and
(2) reduce pain related to neurogenic inflammation. Since we
concentrated on GAT1, for this study, as a pharmacological
tool we used tiagabine, a highly selective GAT1 inhibitor.
We tested it in a mouse model of OCD, namely, the marble
burying test, and in a mouse model of neurogenic pain, i.e., the
capsaicin test.31,32 Tiagabine is an anticonvulsant drug used to
treat partial seizures in humans. Recent results from clinical
trials indicate that it might be also effective in patients suffering
from pain33,34 or mood disorders35−37 but its effects on the
symptoms of OCD or pain related to neurogenic inflammation
have not been investigated.
■ RESULTS
Figure 1 exhibits the chemical structures of studied com-
pounds. Graphical representation of the pharmacophore model
of GABA-uptake inhibitors which includes three features, i.e.,
A, the acidic center; B, the basic center; C, the diaryl center is
shown in Figure 2. The structure of investigated compounds
were compared to the proposed pharmacophore triangle by
measurements of the appropriate distances and angles. All
intramolecular distances and angles relevant to the pharmaco-
phore (i.e., a, b, c, ∠ABC), were measured and collected in
Table 1. The investigated active structures of the studied com-
pounds are compared using superimposing procedure and are
shown in Figure 3. Figures 4 and 5 illustrate the binding modes
between hGAT1 and 15 studied compounds. The results of
docking experiments, such as the complex binding energy,
specific hydrogen bond components, and hydrogen bond
Figure 1. Chemical structure of the investigated compounds. Carbons at a tetrahedral stereogenic center are designated with an asterisk.
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energies, lengths, and angles are shown in Supporting
Information Table 1S. Figures 6 and 7 present the results of
the respective pharmacological studies.
Molecular Studies. Pharmacophore Model Analysis. In
the early 1990s, N’Goka et al. proposed the pharmacophore
model for the GABA-uptake inhibitors.38 According this concept
(Figure 2), it was defined as following pharmacophore regions
such as amino acid, linker and diaryl regions, respectively.
The intermolecular distances and angle in the proposed
pharmacophore model are as follows: a, the distance between
the center of acidic and basic group; b, the distance between N
nitrogen atom of amino moiety and the center of diaryl region;
c, the distance between COOH group and center of diaryl ring;
∠ABC, the angle between sections a and b (specified
extended-folded conformations of the studied compounds).
The investigated active structures of the studied compounds
are compared by means of the distances and angle listed below
(Table 1). It was found that the distances between the
pharmacophore features, estimated for the selected ligands, are
within the following range: a = 3.9−5.6 Å; b = 3.8−7.8 Å; c =
3.4−9.7 Å; ∠ABC = 42−147°.
To obtain additional information concerning the shape of
the investigated drug, the active conformations were chosen for
superimposition. The atoms (except hydrogen atoms) com-
mon to these molecules were selected for the fitting procedure.
Their similarity was calculated as RMS fit. The RMS routine
provided estimates of how closely molecules fit to each other.
The lower the RMS value, the better the similarity. The docked
structures of the studied molecules were compared by super-
imposing them using a least-squares algorithm that minimizes
the distances between the corresponding non-hydrogen atoms
as shown in Figure 3. The analysis of similarity of obtained
active structures shows that all 17 compounds adopt very simi-
lar conformation in the target site of the protein. The only
significant deviation of the structure concerns diaryl regions.
Molecular Docking Studies: The Glial Selective GABA
Uptake Inhibitor Nipecotic Acid Group Tiagabine and RPC
425. From the molecular docking study, it was found a little
stronger interaction with hGAT1 for RPC 425 (i.e., R-RPC
425 = −7.95 and S-RPC 425 = −7.74 kcal/mol, respectively)
than tiagabine (i.e., R-tiagabine = −7.23 and S-tiagabine =
−6.98 kcal/mol, respectively).5 The obtained results reveal
that R and S enantiomers of RPC 425 form single H-bonds
with hGAT1 (Figure 4). The complex of R-RPC 425-hGAT1
has one normal H-bond in which the COO− group donates
energetically moderate (−4.13 kcal/mol), short (2.11 Å), and
nonlinear (164°) interaction to Tyr139. While the interaction
between S-RPC 425 and residues of hGAT1 involve the
carboxylic end of S-RPC 425 and Met458 and Ser459 that
interact via bifurcated H-bond. In the bifurcated hydrogen
bond the major component is Ser459 and the minor com-
ponent is Met458 but in this case the associated energies are
low (EHB = −1.33 and −0.60 kcal/mol, respectively). The
distances of the hydrogen bonds lie in the range from 1.84 to
2.02 Å, and due to this the three-centered hydrogen bond is
not symmetric (Figure 4).
Table 1. Distances (Å) and Angles (deg) between
Pharmacophore Features for Compounds Studied in the
Current Work
compd a (Å) b (Å) c (Å) ∠ABC (deg)
R-tiagabine 4.3 4.4 9.6 147
S-tiagabine 4.8 4.3 4.1 54
R-RPC 425 3.5 5.7 9.7 69
S-RPC 425 3.5 5.5 7.8 116
R-EF 1500 3.9 4.4 3.4 50
S-EF 1500 4.0 5.5 6.4 94
R-EF 1502 4.1 6.4 4.7 42
S-EF 1502 3.2 7.5 8.1 91
SKF 89976A 4.5 5.8 7.4 83
SKF 100330A 4.5 5.1 6.5 102
DPB-THPO 4.4 6.1 6.7 75
R-DPB-N-Me-exo-THPO 3.7 5.7 7.7 117
S-DPB-N-Me-exo-THPO 3.9 6.6 6.3 72
CI 966 4.3 5.4 7.6 127
NNC 711 4.1 5.1 8.8 148
R-Lu-32-176B 3.8 3.8 4.6 76
S-Lu-32-176B 3.9 4.8 3.9 56
Figure 3. Superimposition of the investigated docked structures of
(a) the nipecotic analogues and (b) the THPO analogues.
Figure 2. Graphical representation of the pharmacophore model of GABA-uptake inhibitors. Pharmacophore features: a, b, c, ∠ABC.
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SKF 89976A and SKF 100330A. It was found that both SKF
89976A (N-(4,4,-diphenyl-3-butenyl)-nipecotic acid) and SKF
100330A (N-(4,4,-diphenyl-3-butenyl)-guvacine) could inter-
act with hGAT1 via one H-bond (Figure 4). The binding
energies of SKF 89976A and SKF 100330A are −8.34 and
−7.94 kcal/mol, respectively. As shown in Figure 4S, the car-
boxylic moieties of both compounds accept H-bonds. SKF
89976A creates the bifurcated bond to Met458 and Ser459,
while SKF 100330A interacts via normal H-bond with Tyr140.
The latest interaction involves the COO group of SKF
100330A with the oxygen atom of side-Ph−O−H of the
Tyr140 residue. It is almost linear (177°) with low H-bond
energies (−0.31 kcal/mol). The former interaction involved
in a NH···COO···NH bifurcated H-bond with major compo-
nent of Ser459 (EHB = −5.26 kcal/mol, θ = 160°) and the
minor component of Met458 (EHB = −3.46 kcal/mol, θ =
144°). All calculated distances of the H-bond lie in the range
2.01−2.19 Å.
NNC 711 and CI 966. Both compounds can interact with
hGAT1 (Figure 4). The carboxylic end of CI 966 [1-[2-bis[4-
(trifluoromethyl)phenyl]-methoxy ]ethyl]-1,2,5,6-tetrahydro-
3-pyridinecarboxylic acid, having two oxygen atoms, forms
two interactions: one oxygen is involved in a NH···O···HN
bifurcated hydrogen bond incorporating the NH from Met458
and the NH from Ser459, while the second oxygen binds NH
from Leu460 via a two-centered hydrogen bond. In the bifur-
cated hydrogen bond the major component is Met458 and the
minor component is Ser459 but in this case the associated H-bond
energies are relatively small (i.e., −4.43 and −3.81 kcal/mol
respectively). The distances associated with the three
centered H-bonds lie in the range 1.89−2.21 Å with θ ∈
(149−164°) and due to this it is far from symmetric inter-
action. The highest hydrogen bond energy (−7.43 kcal/mol)
was found for the normal H-bond which is almost linear (171°).
Surprisingly, the addition of (1-2(((diphenylmethylene)amino)-
oxy)ethyl) moiety to guvacine end-capping completely different
Figure 4. Binding modes between hGAT1 and investigated drugs RPC 425 6-(R,S)-((4,4-bis(3-methylthiophen-2-yl)but-3-en-1-yl)(methyl)-
amino)cyclohex-1-ene-1-carboxylic acid; SKF 89976A (N-(4,4,-diphenyl-3-butenyl)-nipecotic acid) and to guvacine yielded SKF 100330A (N-
(4,4,-diphenyl-3-butenyl)-guvacine); NCC 711 (1-2(((diphenylmethylene)amino)oxy)ethyl)-1,2,4,6-tetrahydro-3-pyridinecarboxylic acid; CI 966
[1-[2-bis[ 4-(trifluoromethyl)phenyl]-methoxy]ethyl]-1, 2,5,6-tetrahydro-3-pyridine-carboxylic acid. Compound (ball and stick), residues involved
in hydrogen bonding with the ligand (black) along with their hydrogen bonds (dashed green lines).
Figure 5. Binding modes between hGAT1 and investigated drugs: EF1500 ((R,S)-4-[N-[1,1-bis(3-methyl-2-thienyl)but-1-en-4-yl]-N-amino]-
4,5,6,7-tetrahydrobenzo[d]isoxazol-3-ol); EF1502 ((R,S)-4-[N-[1,1-bis(3-methyl-2-thienyl)but-1-en-4-yl]-N-methylamino]-4,5,6,7-
tetrahydrobenzo[d]isoxazol-3-ol); N-DPB-N-Me-exo-THPO: (R,S)-N-diphenylbutenyl-N-methyl-3-hydroxy-4-amino-4,5,6,7-tetrahydro-1,2-benzi-
soxazole; N-DPB-THPO: 5-(4,4-diphenylbut-3-en-1-yl)-4,5,6,7-tetrahydro[1,2]oxazolo[4,5-c]pyridin-3-ol; Lu-32-176B (R,S)-(N-[[4,4-diphenyl-
but-3-en-1-yl]amino]-4,5,6,7-tetrahydro-1,2-benzoxazol-3-ol). Compound (ball and stick) residues involved in hydrogen bonding with the ligand
(black) along with their hydrogen bonds (dashed green lines).
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character of interaction with hGAT1 residue. In NNC 711-
hGAT1 complex it is observed interaction between heteroatoms
of the N-ethoxy organic function and residues of hGAT1. Both
act as acceptors: the oxygen atom binds NH from Gly65 and the
nitrogen atom binds OH from Tyr140. As it can be seen from
Figure 4S the interactions are nonlinear (142° and 162°) with
low H-bond energies (−2.44 and −3.28 kcal/mol) and com-
parable bond lengths (2.03−2.04 Å).
Molecular Docking Studies: The Glial Selective GABA Uptake





In the preliminary analysis of the docking, it was observed
that the R enantiomer of these compounds strongly interacts
with hGAT1 (Figure 5). The interactions with the active site of
the protein had binding energies of R-EF1500 = −9.19 and
R-EF1502 = 9.69 kcal/mol and S-EF1500 = −8.34 and S-EF1502
= −8.86. The comparison of the obtained binding energy leads
to the conclusion that all these interactions have comparable
potency but slightly more potent is EF1502. The obtained results
revealed that S-EF1502 forms two H-bonds and remainder
compounds form only one. The complex of R-EF1500-hGAT1
has one normal H-bonding in which exocyclic amine group
donates energetically moderate (−5.04 kcal/mol) short
(1.96 Å) and nonlinear (150°) interaction to Tyr139. Simi-
larly, the complex of R-EF1502-hGAT1 has one normal H-bond
in which the oxygen atom of the tetrahydro-1,2-benzoxazol-3-ol
ring donates energetically strong (−7.72 kcal/mol), short
(1.87 Å), and almost linear (170°) interaction to Tyr140
(Figure 5). While the interaction between S-EF1500 and
residues of hGAT1 involves the SER396 and exocyclic hydroxyl
group donating energetically weak (−0.32 kcal/mol), short
(2.13 Å), and almost linear (174°) interactions. The inter-
action of S-EF1502 and residues of hGAT1 involves the
4,5,6,7-tetrahydro-1,2-benzoxazol-3-ol amine group that inter-
acts via one normal H-bond and the hydroxyl group of
S-EF1502 that interacts via bifurcated H-bond (Figure 5). The
interaction concerning the aromatic nitrogen atom of the
tetrahydro-1,2-benzoxazol-3-ol ring donates one H-bond to
Leu460. This interaction is almost linear (i.e., 167°) with a
moderate H-bond energy (3.81 kcal/mol) and a long bond
length (2.23 Å). Whereas the hydroxyl end of EF1502 acts as
an acceptor to the NH group of MET458 and donor to the
CO of SER456’s carboxyl group. From the data in Table 2S
and Figure 5, it can be seen that this bifurcated system is
nonlinear (138−148°), energetically and geometrically almost
symmetric. The distances associated with the hydrogen bonds
lie in the range from 1.94 to 2.24 Å. with a moderate energy
between −2.62 and −2.39 kcal/mol.





We studied R/S-N-DPB-N-Me-exo-THPO structure inter-
action with hGAT1 via single H-bond and DPB-THPO inter-
action via two normal H-bond (Figure 5). The interactions
with the active site of the protein show binding energy of R-N-
DPB-N-Me-exo-THPO ≈ R-N-DPB-N-Me-exo-THPO ≈ −9.5.
In the case of the R enantiomer, the 4,5,6,7-tetrahydro-1,2-
benzoxazol-3-ol amine group donates one normal H-bond to the
CO of the carboxyl group of ASP451. This interaction is
approximately nonlinear (152°) with moderate energy, i.e.,
−5.15 kcal/mol and a small bond length equal 1.91 Å. Whereas
in case of the S enantiomer, the oxygen atom of 4,5,6,7-
tetrahydro-1,2-benzoxazol-3-ol acts as acceptor in the H-bond
with TYR140. This interaction is approximately linear (177°)
with low energy, i.e, −2.78 kcal/mol and a long bond length
equal to 2.23 Å. The DPB-THPO-hGAT1 complex has a
binding energy slightly less (−8.78 kcal/mol) thanthat of R/S-
N-DPB-N-Me-exo-THPO. Its H-bonds are formed between
the oxygen atom of 4,5,6,7-tetrahydro-1,2-benzoxazol-3-ol ring
and TYR139 and between the 4,5,6,7-tetrahydro-1,2-benzox-
azol-3-ol amine group and ASP451.
R/S-Lu-32-176B. R/S-Lu-32-176B is R/S-(N-[[4,4-diphenyl-
but-3-en-1-yl]amino]-4,5,6,7-tetrahydro-1,2-benzoxazol-3-ol).
The R/S-Lu-32-176B docking experiment revealed that this
molecule can interact with the active site of the human protein
models with binding energy comparable (for R enantiomer
EB = −9.09 and for S enantiomer EB = −9.00 kcal/mol) to
those found for R-EF1500 and R-EF1502 complex models
(Figure 5). The R/S-Lu-32-176B-hGAT1 complex is formed
via single key interaction with residues of hGAT1. In the case
of the R enantiomer, the 4,5,6,7-tetrahydro-1,2-benzoxazol-3-ol
amine group donates one normal H-bond to the CO of the
Figure 7. Effect of tiagabine on anxiety and obsessive-compulsive
behavior measured in the marble burying test. Results are shown as
the number of marbles buried ± SEM. Statistical analysis: one-way
analysis of variance (ANOVA), followed by Dunnett’s post hoc test.
Statistical significance vs vehicle-treated group: ***p < 0.001.
Number of animals per group: n = 8−10.
Figure 6. Antinociceptive effect of tiagabine in the capsaicin-induced
neurogenic pain model. Results are shown as the duration of the
nociceptive reaction ± SEM. Statistical analysis: one-way analysis of
variance (ANOVA), followed by Dunnett’s post hoc test. Statistical
significance vs vehicle-treated group: ***p < 0.001. Number of
animals per group: n = 8−10.
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carboxyl group of Phe295. This interaction is nearly nonlinear
(160°) with low energy, i.e., −2.13 kcal/mol and a small bond
length equal 2.20 Å. In the case of the S counterpart, a single
interaction was found in which the 4,5,6,7-tetrahydro-1,2-
benzoxazol-3-ol hydroxyl group donates to the carbonyl group
of the ASP451. This interaction is approximately nonlinear
(146°) with weak energy, i.e., −0.61 kcal/mol and a small
bond length equal 1.75 Å.
Pharmacological Part. Capsaicin Test: Neurogenic Pain
Model. Compared to vehicle, tiagabine showed antinociceptive
properties in mice (F(3,37) = 19.07, p < 0.0001). At doses of 8
and 4 mg/kg, it significantly reduced the nociceptive reaction
in mice by over 99% (p < 0.001) and 80% (p < 0.001), respec-
tively. At the lowest dose tested (2 mg/kg), tiagabine reduced
the duration of nociceptive response in mice, but this effect
was not statistically significant (Figure 6).
Marble Burying Test: Obsessive-Compulsive Disorder
Model. In the marble burying test, tiagabine exerted a potent
anxiolytic-like activity reducing obsessive-compulsive behavior
of mice (F(2,27) = 38.50, p < 0.0001). Compared to the vehicle-
treated group, it significantly reduced the number of buried
marbles: at the dose of 8 mg/kg by 73% (p < 0.001) and at the
dose of 4 mg/kg−by 88% (p < 0.001) (Figure 7).
■ DISCUSSION
Notwithstanding that today potent and selective GAT1 inhibi-
tors are available, it is widely accepted that structural require-
ments for compounds acting as inhibitor of GABA uptake are
not clearly understood. The amino acid pharmacophore region
is the GABA mimic part which reflect the zwitterion form of
the GABA analogues (Figure 1). It was found that GABA is
transported by GAT in a somewhat folded conformation
withless than 5 Å separation of charged centers. It was recom-
mended that approximate separation of the a distance can be
sorted as follows: glial (a > 1.6 Å), neuronal and glial (a < 5.0 Å),
and neuronal (a > 5.4 Å) of blocking effect in selective
inhibitions. By incorporation of the basic (−NH2) or acid
(−CO2H) moieties of GABA into ring structures, it has been
possible to immobilize different parts of the molecules and,
furthermore, to develop zwitterionic GABA analogues with
protolytic properties making penetration of the blood-brain
barrier (BBB) possible. Previously, it was discovered that a
number of cyclic amino acids, such as nipecotic acid, iso-
nipecotic acid, guvacine, and isoguvacine, which can be con-
sidered as conformationally restricted GABA analogues, display
in vitro activity as inhibitors of [3H]-GABA uptake.38 However,
a detailed investigation of these compounds revealed that these
cyclic amino acids do not readily cross the BBB. Interestingly,
nipecotic acid was described as potent GAT inhibitor with no
affinity to the receptors. These observations have inspired
researchers to search for diaryl bioisosters of GABA with higher
lipophilic profiles, i.e., lipophilic binding region (preferably
diheterocyclic). Together with a linker region located between
the amino acid and the lipophilic region. This initiated many
syntheses of structurally related lipophilic GABA compounds
and led to the discovery, in 1988, of a highly lipophilic GABA
uptake inhibitor with CNS activity, i.e., tiagabine ((R)-1-[4,4-
bis(3-methyl-2-thienyl)-3-butenyl]-3-piperidine-carboxylic
acid). Tiagabine is the only GABA transport inhibitor that has
been approved as a drug present a therapeutic advantage in the
anticonvulsant and analgesic therapies.39 The result of
pharmacophore analysis for all studied compounds show that
the a distance values are in range of references for glial
transport data (Table 1). It interacts with both neuronal and
glial transport sites for GABA, although much more strongly
with the glial site. In addition, the received angles are far from
extended conformation, and this indicates that they play a role
in biological activation. The superimposition results shows that
all 17 compounds adopt very similar conformation in the target
site of the protein. Based on this we can treat the geometries of
drugs obtained in this study as the active conformation for the
investigated compounds.
Discovery of guvacine and R- and S-nipecotic acid enabled
the use of them as the GABA mimetic moiety in the synthesis
of more potent GAT inhibitors in which the length and elec-
tronegativity of the linker was altered along with the diaromatic
region at the end of the linker. The addition of the 4,4-bis(3-
methylthiophen-2-yl)but-3-en-1-yl group to nipecotic acid
yielded tiagabine.5,40 However, clinical use of tiagabine is
limited by its short half-life and side effects (dizziness, fatigue,
confusion, tremor, ataxia, and nervousness).41 These observa-
tions have inspired researchers to search for new promising lead
structures.42 One of them is β-alanine, a selective but relatively
weak inhibitor of glial GABA uptake.43 Throughout the years,
the β-amino acid backbone of β-alanine have been used for a
number of lipophilic GABA analogues such as RPC 425, i.e.,
6-((4,4-bis(3-methylthiophen-2-yl)but-3-en-1-yl)(methyl)-
amino)cyclohex-1-ene-1-carboxylic acid. Tiagabine and RPC
425 differ by exchange nipecotic acid via 6-aminocyclohex-1-ene-
1-carboxylic acid and are structurally closely related to each
other (Figure 1). Additionally, in tiagabine the chiral center is
the carbon atom α to the carboxyl group but in RPC 425 the
chiral center is the carbon atom α to the amino group. The
detailed analysis of the docking study of tiagabine were
presented in our previous work.5 A number of pharmacological
facts, such as a 2-fold higher selectivity for astrocytic GAT com-
pared to neuronal44 with our pharmacophore analysis (Table 1, for
R and S tiagabine a < 5 Å), make more understandable its higher
selectivity for astrocytic GAT. In the in vivo part of the present
study, using two behavioral assays, i.e., the capsaicin test and the
marble burying test, we have shown that tiagabine, by inhibiting
GAT1, (1) effectively attenuates pain related to neurogenic
inflammation and (2) is able to reduce severity of OCD-like
symptoms in mice exposed to stressful conditions (here: unfamiliar
objects in the environment). Simultaneously, the results obtained
indicate that GAT1 might be a potential drug target for agents
that are useful in the treatment of neurogenic pain and OCD.
In contrast, RPC 425 was found to be 7-fold more selective
inhibitors of the BGT1 GABA-transporter subtype than
GAT1.45,46 The BGT1 is expressed at much lower levels in
the brain and has primarily been assigned to the astrocytes.47
It is widely accepted that BGT1 plays an important role for
inactivation of GABA as neurotransmitter12,48 but due to very
low expression levels in the brain (approximately100−1000
times lower than GAT1) its functional role in seizure control is
controversial.42 Obtained pharmacophore results for the
distance a of the RPC 425 (Table 1, a = 3.5 Å) strongly
support its high affinity for astrocytes. Docking data support
the hypothesis that RPC 425 could interact not only with
BGT1 but also with GAT1, and in a dose dependent manner
due to its half maximal inhibitory concentration data (BGT1
IC50 = 45 μM, GAT1 IC50 = 307 μM).
45,46
The addition of 4,4-diphenyl-3-buteny slide chains to nipecotic
acid yielded SKF 89976A (N-(4,4,-diphenyl-3-butenyl)-nipecotic
acid) and to guvacine yielded SKF 100330A (N-(4,4,-diphenyl-3-
butenyl)-guvacine) with the highest potency at the human
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GAT1. Both compounds were potent competitive inhibitors of
GABA uptake and were not substrates for the carriers.11 Each
agent was 20-fold more potent than the cognate parent com-
pound in competing GABA interaction with carriers in rat
diencephalic membranes. Pharmacological studies indicate that
the family of compounds represented by SKF 89976A and SKF
100330A may have clinically relevant anticonvulsant activity.49
N-Alkylation of guvacine to yield [1-[2-bis[ 4-(trifluoromethyl)-
phenyl]-methoxy ]ethyl]-1, 2,5,6-tetrahydro-3- pyridine-carboxylic
acid, i.e., CI 966, and (1-2(((diphenylmethylene)amino)oxy)-
ethyl)-1,2,4,6-tetrahydro-3-pyridinecarboxylic acid, i.e., NNC 711,
agents slightly more potent than guvacine at inhibiting GABA
uptake. It was estimated that the NNC 711 is 50−200-fold more
potent than R,S-nipecotic acid and guvacine. The NNC 711
was 85-fold more potent than the pattern compound guvacine
in inhibiting GABA uptake into a crude synaptosome prepara-
tion and remains the most potent GABA uptake inhibitor
reported to date.16,50 As an inhibitor of GABA transport, it is
found to have 40 000-fold higher selectivity for GAT1 com-
pared to GAT3.16 CI 966 exhibited potent anticonvulsant
activity in several rodent models of seizure.11 CI 966 and NNC
711, like tiagabine, have as 2-fold higher selectivity for astro-
cytic GAT compared to the neuronal one.1 CI 966 was inves-
tigated as potent anticonvulsant, anxiolytic and neuroprotective
medication but due to the serious incidence of several adverse
effects at higher doses these works were stopped.40 Moreover, it
was found that tiagabine at the same dosage did not expose the
same adverse effects.51 Merging the above-mentioned docking
data with pharmacological results indicates that the differences in
the interactions nature of hGAT1 residues with CI 966 and
NNC 711 and tiagabine failed clinical tests of CI 966. On the
other hand some researchers admit possibility that the initial
doses of CI 966 studied in humans were too high.51
EF1502 is a structural hybrid of tiagabine and N-Me-exo-
THPO.52 EF1502 was found to possess a reasonably potent
and broad-spectrum anticonvulsant profile and a protective index
comparable to that of the selective GAT1 inhibitor tiagabine.53
The R-EF1502 is approximately 20-fold more potent than
S-EF1502. But the racemic mixture EF1502 equipotently
inhibits astrocytic and neuronal GAT. The EF1502 inhibits
both GAT1 and BGT153 and it is subsequently reported to act
synergistically with the GAT1 inhibitor tiagabine in protection
against seizures. Historically, these observations were consid-
ered as evidence for functional role for BGT1 in seizure
control.12,31,42 These pharmacological data are in agreement
with our pharmacophore analysis. As can be seen from Table 1,
the distances a > 4 Å prove strong interaction to astrocyte cells.
Combination of the above-mentioned pharmacological data
with our docking data indicates that an anticonvulsant com-
ponent appears with a high affinity to hGAT1.
The introduction of the lipophilic diaromatic side chain
4,4-diphenylbut-3-en-1-yl (DPB) at these compounds gave
very potent GABA uptake inhibitors. The DPB substituted
THPO and N-Me-exo-THPO compounds were competitive
and noncompetitive inhibitors, respectively at GAT1. DPB-
THPO displayed a 30-fold higher inhibitory activity than the
parent compound with regard to GABA transport by GAT1
and did not display proconvulsant activity.11 Additionally, it
is about 4-fold more potent to astrocytic than neuronal
transporter.54
Lu-32-176B, like tiagabine, is a highly selective GAT1 blocker,
with 2-fold higher selectivity for astrocytic GAT compared to the
neuronal one, and in combination with EF1502 it exerted a
synergistic anticonvulsant effect at all dose mixtures.1,55 The last-
mentioned studies, indicating another prove a functional role for
BGT1 in the control of neuronal excitability and possible utility
for contributed to the anticonvulsant activity of EF1502.52
Additionally the Lu-32-176B as well as EF1500, both of which
are lipophilic analogs of exo-THPO, did not display any affinity
for mGAT2-4.
■ CONCLUSION
Modern research delivers novel solutions and new potential
therapeutic targets. About 30 years ago, it was assumed that
astrocytes participate in the intercellular communication
processes. Currently, it is widely accepted that together with
neurons astrocytes play a pivotal role in regulating normal
brain functions. Nowadays, due to the fact that subpopulations
of astrocytes and neurons share a complementary set of
channels and receptors,45 the role of astrocytes was extended
to the pathophysiological role in epilepsy and/or pain and
other CNS-related disorders.46 The domain of a single human
astrocyte has been estimated to contact up to 2 million
synapses. In human cortex, astrocytes are more than 2-fold
larger in diameter than those in their rodent counterparts. The
transport systems for GABA in neurons and glial cells have
remarkably similar properties. GABA analogues in which the
pharmacophore distance a are separated by not less than about
5.4 Å selectively inhibit the neuronal transport of GABA.
Analgesic activity of GAT1 inhibitors has been shown
previously.4,5,34,51 Interestingly, none of these studies focused
strictly on the role of GAT1 in pain resulting from neurogenic
inflammation. In the present study, for the assessment of the
role of GABAergic neurotransmission in this phenomenon, we
used capsaicin, a Transient Receptor Potential Vanilloid sub-
type 1 (TRPV1) agonist.56 This compound is widely regarded
as a potent inducer of neurogenic inflammation by acting on
subsets of primary sensory neurons expressing heat-sensitive
TRPV1 channels to release proinflammatory neuropeptides,
such as substance P or calcitonin gene-related peptide.57
Here, we demonstrated a strong, statistically significant, and
dose-dependent antinociceptive activity of GAT1 inhibitor−
tiagabine. Our results are in line with data obtained by other
authors. These studies showed that GABA reduced capsaicin-
induced pain sensation in humans,29 while GABAergic agents,
such as, e.g., sodium valproate or allopregnanolone, are able to
abort neurogenic inflammation in migraine headache, block
dural plasma protein extravasation and attenuate nociceptive
signal transmission by enhancing GABAergic neurotransmis-
sion via GABA-A receptor-mediated mechanisms.58,59 Similar
to those findings, in our present study, tiagabine, by inhibiting
GAT1 function, enhanced GABAergic neurotransmission,
which resulted in analgesia and attenuation of neurogenic
inflammation.
GABA deficits play a key role in the development of anxiety-
related disorders, including OCD.58 Although numerous
randomized, placebo-controlled trials in OCD patients proved
acute and long-term efficacy and safety of selective serotonin
reuptake inhibitors, which makes them drugs of choice in the
pharmacological management of OCD,60 the decrease in
GABAergic neurotransmission has been also linked with the
development of OCD symptoms.61,62
In mice, the marble burying test is regarded as a “gold
standard” behavioral model that mimics human OCD symp-
toms, in particular, compulsions.63 This test utilizes a common
behavior in mice, i.e., burying objects present in the
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environment. The results obtained for tiagabine in the marble
burying test show that the enhancement of GABAergic neuro-
transmission results in the anxiolytic-like action and a reduc-
tion of obsessive-compulsive behavior, which was also
described elsewhere.4,34
Our present study showing anti-OCD properties of tiagabine
in a mouse model is in line with a case report of an OCD
patient that confirmed that the adjunction of tiagabine
(15 mg/day) to a fluvoxamine (400 mg/day)-risperidone
(1 mg/day) combination resulted in a significant attenuation of
OCD symptoms. It was therefore concluded that the enhanced
inhibitory GABAergic neurotransmission due to GAT1 inhibi-
tion reduces excitatory glutamatergic transmission in the cortico-
striato-thalamic system, which presumably constitutes the basis
for of OCD symptoms.64
Combination of the above-mentioned facts prove that a
selective modification of GABA neurotransmission is a valuable
approach to the search for new anticonvulsant, analgesic and
anxiolytic drugs. Presented data of docking studies strongly
support the hypothesis that the pharmacological action of the
studied drugs are related to potency of their chemical inter-
actions with hGAT1. Studied compounds exhibit higher binding
energy to the hGAT1 simultaneously acting as selective inhibi-
tors of astrocytic GABA uptake. According to the results of the
present in vivo study, binding to the GABA transporter isoform
1 may be responsible for a potent pharmacological action.
■ METHODS
In Silico Studies. The calculation procedures applied in the study
are typical for processing of docking studies.
Ligand Preparation. The 3D structures of 16 compounds
(Figure 1) were downloaded from the ZINC database.65 Structures
of these compounds were constructed using the GaussView 4.1.2
program. Subsequently, geometry optimization was carried out for
each compound using the Gaussian version 09.66 Finally, the Gasteiger
charges were assigned to each compound using the Autodocktools
program.67
Human GAT-1 Transporter Preparation. The protein sequence
for the hGAT-1 protein was gained from the Swiss-Prot database68
(accession number P30531). For generating the hGAT-1 structure,
we took the alignment from Beuming et al.69 This alignment has been
refined using membrane protein-specific algorithms and by consid-
ering experimental data. Sequence identity between the template and
the modeled sequence is 47% and according to our best knowledge
this is the highest identity available now. Molecular docking was
performed using the Autodock 4.2 suite of program.67
Molecular Docking. Molecular docking was performed using the
Autodock 4.2 suite. Both the protein and ligands were saved in pdbqt
format. A grid box with a dimension of 60 × 60 × 60 Å3 and a grid
spacing of 0.375 Å, which is large enough for a free rotation of a
ligand, was built centered on the center of the mass of the catalytic
site of transporter according to place of GABA binding. The ligand
binding site is formed by a shell of 12 surrounding important residues
such as Tyr60, Ala61, Gly63, Gly65, Leu136, Tyr140, Phe294, Ser295,
Tyr296, Gly297, Leu300, and Thr400.70 The docking calculations
were carried out using the Lamarckian genetic algorithm. The
optimized docking parameters were set as follows: (i) the number of
genetic algorithm run was 100; (ii) the population size was 150;
(iii) the maximum number of energy evaluations was 250 000 per run;
(iv) and the maximum number of generation in the genetic algorithm
was 27 000. All other docking parameters were set at their default
values. A cluster analysis was performed on the docked results using a
RMS tolerance of 2 Å. The best docking result in each case was
considered to be the conformation with the lowest binding energy.
Hydrogen bindings between docked potent agents and related
macromolecule were analyzed using Autodock tools program ADT,
version 1.5.4.71
Pharmacological Studies. Animals and Housing Conditions.
Adult, 4-week old CD-1 male mice weighing 20−25 g were used in
the behavioral tests. The mice were purchased from the animal
breeding farm at the Faculty of Pharmacy, Jagiellonian University
Medical College in Krakow. According to the European Parliament
directive 2010/63/UE, the animals were kept in standard conditions
(22 ± 2 °C, relative humidity 55 ± 10%, 15 ACPH) with access to
food and water ad libitum. The light−dark cycle was 12:12. After the
experiments, mice were euthanized by cervical dislocation. All the
procedures concerning in vivo assays were approved by the Local
Ethics Committee of the Jagiellonian University (ZI/40/2016).
In Vivo Tests. Capsaicin Test: Neurogenic Pain Model. Sixty
minutes before the capsaicin test the mice were administered vehicle
(1% Tween 80 solution, Sigma-Aldrich, Poland) or tiagabine (Tocris
Bioscience, Germany) in a constant volume of 10 mL/kg.
Immediately before the assay, a solution of capsaicin (1.6 μg in
20 μL 0.9% saline) was injected intraplantarly into the right hind paw
of each mouse. Then the animals were gently placed under glass
beakers and observed for the next 5 min. The duration of the
nociceptive reaction, i.e., licking, shaking, or biting the injected paw,
was measured.72
Marble Burying Test: OCD Model. The test was performed
according to a method described by Broekkamp et al.44 with some
minor modifications.45 Briefly, the mice were placed individually into
plastic cages identical to their home cages. The cages contained a
5 cm layer of sawdust and 20 black glass marbles (1.5 cm diameter)
which were gently spaced in the cage, equidistant in a 4 × 5
arrangement. After a 30 min testing period, the mice were removed
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(9) Bröer, S., and Gether, U. (2012) The solute carrier 6 family of
transporters. Br. J. Pharmacol. 167, 256−278.
(10) Scimemi, A. (2014) Structure, function, and plasticity of GABA
transporters. Front. Cell. Neurosci. 8, 1−13.
(11) Clark, J., and Clark, W. (2001) Pharmacology of GABA
transporters. In Pharmacology of GABA and Glycine Neurotransmission
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